MetaCap

Ginkgo Bioworks (DNA) vs 4D Molecular Therapeutics (FDMT)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

4D Molecular Therapeutics (FDMT) has outperformed Ginkgo Bioworks (DNA) over the past year, losing 5.6% versus a loss of 8.7%. Over five years, FDMT leads with a -53.6% price change compared with -98.5% for DNA. 4D Molecular Therapeutics is the larger company by market cap ($576.8 million vs $483.5 million), about 1.2 times the size.

4D Molecular Therapeutics converts more of its revenue into profit, with a net margin of -164.4% versus -183.8%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

DNA-8.69%FDMT-5.63%
+89%+25%-40%
Nov 21, 20251 yearNov 20, 2026
DNA-98.61%FDMT-55.64%
+53%-27%-106%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

DNA versus FDMT key metrics
MetricDNAFDMT
Share price$7.46$10.23
Market cap$483.54M$576.76M
1-day change-9.02%-4.57%
YTD return-10.23%+36.40%
1-year return-8.69%-5.63%
5-year return-98.45%-53.61%
EPS (TTM)$-4.24$-2.70
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$170.16M$85.21M
Revenue growth (YoY)-25.06%+230194.59%
Net income (latest FY)$-312.76M$-140.11M
Operating margin-185.29%-187.24%
Net margin-183.81%-164.43%
52-week high$18.22$16.93
52-week low$5.37$6.96
Distance from 52-week high-59.06%-39.57%
Analyst consensusunderperformstrong_buy
Avg. price target upside+7.24%+174.58%
Average volume2.53M967.00K
Shares outstanding53.94M56.38M
Employees485196
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • 4D Molecular Therapeutics is more profitable, keeping -164.4 cents of every revenue dollar as net income versus -183.8 cents for Ginkgo Bioworks.
  • 4D Molecular Therapeutics grew revenue faster in its latest fiscal year (+230194.59% vs -25.06%).

About Ginkgo Bioworks

DNA stock →

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 485 employees

About 4D Molecular Therapeutics

FDMT stock →

4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. The company's lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 196 employees

DNA vs FDMT FAQ

Which is bigger, Ginkgo Bioworks or 4D Molecular Therapeutics?

4D Molecular Therapeutics (FDMT) is larger, with a market capitalization of $576.76M compared with $483.54M for Ginkgo Bioworks (DNA).

Which stock has performed better over the past year, DNA or FDMT?

FDMT returned -5.63% over the past 12 months, compared with -8.69% for DNA (price return, excluding dividends). Past performance does not predict future results.

Are Ginkgo Bioworks and 4D Molecular Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons